Retro Bio
About Retro Bio
Retro Bio develops therapies aimed at meaningfully reversing age-related diseases to extend healthy human lifespan. The company targets cellular drivers of aging to design therapeutics, leveraging approaches like single-cell multi-omics, pooled perturbations, and targeted delivery systems to intervene in aging processes. They pursue translating aging biology insights from proof-of-concept in mammals to human clinical applications, operating with a rapid-iteration, vertically integrated approach. Based in the United States, Retro Bio aspires to become a generational pharma company with a culture of rigor and impact.
Recent News
Vitalist Bay Returns: Four Day Longevity Festival in the Bay Area, May 14 to 17
Retro Biosciences Starts a Safety Trial for an Autophagy Promoter
Wealth Is Health, Insider Betting & Trump Will See Himself in Court
The Longevity Startup That Already Has the Data Altos Labs Is Seeking: Hidden in Plain Sight
A Great Deal More Funding for the Development of Partial Reprogramming Therapies
STAT+: Longevity Startup Retro Biosciences Says Latest Fundraising Values It at $1.8 Billion
Sam Altman's Court Testimony Reveals $2.5 Billion Personal VC Portfolio
Your Next Dog May Live Longer
Free Radicals Podcast (Longevity / Biotech Oriented)
Umanitek Launches Guardian Agent to Tackle AI Hallucinations, Deepfakes and Identity Abuse
Life Biosciences Prepares First Human Trial of Partial Cellular Reprogramming for Glaucoma
Longevity Science Picks up Steam in Pharma
The Tech Billionaires Behind the Immortality Movement
This Method to Reverse Cellular Aging Is About to Be Tested in Humans
Tender Offer for Recordati; Sobi's Gout Drug Passes Phase 3 Test
Why “Reprogramming” Is the Buzziest Approach to Reversing Aging Right Now
AI Services And Robotics Lead Diverse Crop Of 29 New May Unicorns As SpaceX, Anthropic And OpenAI Line Up Blockbuster Exits